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Sir,
The presence of CD4þCD25þ regulatory T cells (Treg) in cancer
patients might be, in part, responsible for downregulation of
antitumour immune responses. Schaefer et al (2005) have shown
the importance of Treg in defining the immune profile of cancer
patients, illustrating the role of these cells in downregulating functions
of other T-cell subsets. Their hypothesis was that lymphocyte
homeostasis disrupted by the presence of tumour fails to normalise
following successful therapy. Wei et al (2005) recently assessed the
possible synergy of immune reactivity to defined tumour- and
self-antigens following reduction of CD4þCD25þ Treg. In a Treg-
deprived environment, tumour cells primed the immune system,
with consequent tumour regression. Treg-depletion enhanced auto-
immunity to mouse thyroglobulin (mTg) in resistant BALB/c
mice. Concurrent tumour regression and mTg immunisation
resulted in further elevation of both antitumour and anti-mTg
immunity.
There are various inhibitory mechanisms in T cells to prevent
pathological autoimmunity. Blocking CTLA4 on T cells or
depleting CD25þ Treg is sufficient to break self tolerance, causing
nonspecific autoimmune pathologies (Phan et al, 2003). On the
other hand, an association between autoimmunity and a favour-
able antitumour effect has been reported. Anti-CTLA-4 Ab given to
patients with metastatic melanoma induces durable objective
clinical responses associated with the induction of autoimmune
side effects. The autoimmune and antitumour effects seen after
CTLA-4 blockade appear to act through direct activation of CD4þ
and CD8þ effector cells. In addition, inhibition of a signaling
inhibitor in antigen-loaded dendritic cells (DCs) can induce a
tumour-associated antigen-specific pathological autoimmune re-
sponse against tumour. SOCS1-silenced DCs effectively break
tolerance at the host level and cause self antigen-specific
autoimmune pathologies against normal tissues but also against
tumours (Evel-Kabler et al, 2006).
As interferon alfa-2b has the ability to induce an immune
response against autoantigens with serologic and clinical mani-
festations of autoimmunity, it is possible that it also induces an
immune response against tumours. The appearance of autoanti-
bodies or clinical manifestations of autoimmunity during treat-
ment with high-dose adjuvant interferon alfa-2b was associated
with statistically significant improvements in relapse-free survival
and overall survival (Gogas et al, 2006).
By contrast, the early presence of autoantibodies in the serum
has been described to correlate with an unfavourable prognosis (de
Visser et al, 2006). The occurrence of autoantibodies in the serum
of cancer patients, and interstitial antibody deposition in human
tumours have been widely reported. As CD4þ and CD8þ T-
lymphocytes are important modulators of tissue-damaging B-
lymphocyte responses, considered that Ig deposition occurs in
human premalignant and malignant tissues, imbalanced adaptive-
immune-cell interactions could represent underlying mechanisms
that regulate the onset of chronic inflammation associated with
cancer development (de Visser et al, 2006).
While it could be possible to use autoimmune responses as
surrogate markers to evaluate new treatments (Gogas et al, 2006),
it might be highlighted that individuals with progressive tumours
could produce a higher antigen load, therefore triggering greater
antibody deposition (de Visser et al, 2006).
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